Avion and Acella Pharmaceuticals Provide Statement Related to Avondale Drug Pricing News
December 13, 2017
Avion pharmaceuticals, LLC, and their partner company, Acella Pharmaceuticals recently responded to the recent news surrounding the Avondale Pharmaceuticals product Niacor, a prescription version of niacin. Avion and Acella were made aware of the recent 800 percent price increase for Avondale’s version of niacin, going from $32.46 to $295 per 100 pills. Avion and Acella pharmaceuticals are led by CEO, Art Deas. Mr. Deas has confirmed that both companies were unaware of the Avondale pricing activity, and that neither company has any relationship or communication with Avondale or its CEO Mark Pugh.
“We are aware of the articles in The Financial Times, The Independent and other media outlets concerning Avondale Pharmaceuticals and its pricing strategy which link Avondale to Mark Pugh, the former CEO of both Acella Pharmaceuticals and Avion Pharmaceuticals,” stated Art Deas, CEO of Acella Pharmaceuticals and Avion Pharmaceuticals. “We would like to make clear that, on March 1, 2016, Mr. Pugh was removed as an officer and member of the Board of Managers of both Acella Pharmaceuticals and Avion Pharmaceuticals. Since that time, Mr. Pugh has not been involved in the operation or management of either company. Moreover, neither Acella Pharmaceuticals nor Avion Pharmaceuticals, or any of their officers, have any connection with Avondale Pharmaceuticals, Acrogen Pharmaceuticals or their reported pricing strategies,” added Deas.
About Avion Pharmaceuticals, LLC
Avion Pharmaceuticals, LLC is a specialty pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the Women’s Heath therapeutic category. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188. For more information, visit wwww.prenate.com.
About Acella Pharmaceuticals, LLC
Acella develops markets, sells and distributes a broad portfolio of non-branded pharmaceutical and other products in the areas of Dermatology, Women’s Health, Pediatrics and other applications. Acella specializes in identifying and bringing to market quality, affordable products to customers and patients. For additional information please contact Acella at 678-325-5189 or visit www.acellapharma.com.